Mepolizumab
- Generic Name
- Mepolizumab
- Brand Names
- Nucala
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 196078-29-2
- Unique Ingredient Identifier
- 90Z2UF0E52
- Background
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is comp...
- Indication
Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patie...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Hypereosinophilic Syndrome (HES), Severe Eosinophilic Asthma
- Associated Therapies
- -
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 24
- Registration Number
- NCT00266565
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00244686
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00097370
- Locations
- 🇮🇹
GSK Investigational Site, Bologna, Emilia-Romagna, Italy
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
- Conditions
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00086658
- Locations
- 🇨🇭
GSK Investigational Site, Bern, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.